Status:
TERMINATED
Effects of Nocturnal Nasal Oxygen on Biomarkers in Sleep Apnea Patients With Heart Failure
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Sleep Apnea
Heart Failure
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Sleep apnea syndrome is clinically defined by frequent pauses in breathing during sleep and symptoms, such as being tired. It can decrease the restfulness of sleep and decreases the level of oxygen in...
Eligibility Criteria
Inclusion
- RDI \> 15
- Symptomatic Heart failure
- Oxygen saturation \< 88% during apnea
- Not currently be on nocturnal oxygen therapy, CPAP, or other PAP therapy
Exclusion
- Hypoxemia requiring oxygen supplementation
- serum creatinine \> 2.5 or on chronic dialysis
- blood pressure \> 160
- pregnant
- chronic physical disability that would prevent subjects from participating in any aspect of the trial
Key Trial Info
Start Date :
November 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2013
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT01431157
Start Date
November 1 2011
End Date
October 1 2013
Last Update
March 10 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Baltimore VA Medical Center
Baltimore, Maryland, United States, 21201
2
University of Maryland
Baltimore, Maryland, United States, 21201